Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 33%
Sell 8%
Strong Sell 0%

Bulls say

CME Group is positioned to see strong growth in the coming years, thanks to its consolidation of key players in the derivatives industry, expanding product offerings, and partnerships with major companies like Google. Additionally, the company's strong focus on technology and innovation, illustrated by its migration to the cloud and use of AI, sets it apart from competitors and will likely drive both top and bottom-line growth. However, the company does face some risks, such as competition and potential regulatory challenges in its new prediction market venture. Nonetheless, CME Group remains a solid investment opportunity with a positive outlook for the future.

Bears say

CME Group is facing significant expenses related to its migration to Google Cloud, expected to complete in 2026. However, the company's lean and scalable business model and focus on shareholder returns through dividends may help mitigate these costs. The company's sustainability efforts, overseen by a dedicated working group and monitored by the board of directors, also point to a long-term strategy for growth and risk management. However, the recent announcement of a partnership with FanDuel to launch a new prediction markets app may provide a potential upside to revenue and EPS in 2026 and beyond.

CME Group (CME) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 12 analysts, CME Group (CME) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $307.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $307.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.